MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis

TSX:MBX • CA59501P1045

0.23 CAD
+0.01 (+4.55%)
Last: Feb 17, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, MBX scores 4 out of 10 in our fundamental rating. MBX was compared to 23 industry peers in the Biotechnology industry. While MBX seems to be doing ok healthwise, there are quite some concerns on its profitability. MBX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year MBX has reported negative net income.
  • In the past year MBX has reported a negative cash flow from operations.
  • In multiple years MBX reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.
MBX.CA Yearly Net Income VS EBIT VS OCF VS FCFMBX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M 4M -4M -6M

1.2 Ratios

  • With an excellent Return On Assets value of -6.00%, MBX belongs to the best of the industry, outperforming 86.96% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -8.08%, MBX belongs to the top of the industry, outperforming 86.96% of the companies in the same industry.
Industry RankSector Rank
ROA -6%
ROE -8.08%
ROIC N/A
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
MBX.CA Yearly ROA, ROE, ROICMBX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • The Gross Margin of MBX (53.02%) is better than 82.61% of its industry peers.
  • MBX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
MBX.CA Yearly Profit, Operating, Gross MarginsMBX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MBX has more shares outstanding
  • MBX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MBX is higher compared to a year ago.
MBX.CA Yearly Shares OutstandingMBX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MBX.CA Yearly Total Debt VS Total AssetsMBX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • MBX has an Altman-Z score of 1.68. This is a bad value and indicates that MBX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.68, MBX is in the better half of the industry, outperforming 78.26% of the companies in the same industry.
  • MBX has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
  • MBX has a Debt to Equity ratio of 0.24. This is comparable to the rest of the industry: MBX outperforms 56.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z 1.68
ROIC/WACCN/A
WACC7.67%
MBX.CA Yearly LT Debt VS Equity VS FCFMBX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

  • MBX has a Current Ratio of 8.48. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 8.48, MBX belongs to the top of the industry, outperforming 91.30% of the companies in the same industry.
  • A Quick Ratio of 5.17 indicates that MBX has no problem at all paying its short term obligations.
  • MBX has a Quick ratio of 5.17. This is amongst the best in the industry. MBX outperforms 86.96% of its industry peers.
Industry RankSector Rank
Current Ratio 8.48
Quick Ratio 5.17
MBX.CA Yearly Current Assets VS Current LiabilitesMBX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for MBX have decreased strongly by -163.28% in the last year.
  • The Revenue for MBX has decreased by -26.81% in the past year. This is quite bad
  • Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 12.05% on average per year.
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%

3.2 Future

  • The Earnings Per Share is expected to grow by 52.75% on average over the next years. This is a very strong growth
  • MBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.96% yearly.
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MBX.CA Yearly Revenue VS EstimatesMBX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
MBX.CA Yearly EPS VS EstimatesMBX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.02 -0.02 0.04 0.06

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
  • MBX is valuated cheaply with a Price/Forward Earnings ratio of 5.69.
  • Based on the Price/Forward Earnings ratio, MBX is valued cheaper than 95.65% of the companies in the same industry.
  • MBX is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.69
MBX.CA Price Earnings VS Forward Price EarningsMBX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

  • MBX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MBX is cheaper than 91.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 138.53
MBX.CA Per share dataMBX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15 0.2

4.3 Compensation for Growth

  • MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as MBX's earnings are expected to grow with 52.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.75%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MBX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MICROBIX BIOSYSTEMS INC

TSX:MBX (2/17/2026, 7:00:00 PM)

0.23

+0.01 (+4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-13
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.76%
Ins Owner ChangeN/A
Market Cap31.87M
Revenue(TTM)18.59M
Net Income(TTM)-2.25M
Analysts80
Price Target0.51 (121.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.69
P/S 1.71
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.32
EV/EBITDA 138.53
EPS(TTM)-0.02
EYN/A
EPS(NY)0.04
Fwd EY17.57%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.13
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6%
ROE -8.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.02%
FCFM N/A
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
F-Score2
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA 34.25
Cap/Depr 44.81%
Cap/Sales 4.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.48
Quick Ratio 5.17
Altman-Z 1.68
F-Score2
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)119.48%
Cap/Sales(3y)5.99%
Cap/Sales(5y)7.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-139.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.85%
OCF growth 3YN/A
OCF growth 5YN/A

MICROBIX BIOSYSTEMS INC / MBX.CA FAQ

What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.


What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a valuation rating of 5 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.


What is the profitability of MBX stock?

MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.